This article provides a description of the company submission, the ERG review and the resulting NICE guidance TA367 issued in November 2015. The ERG critically reviewed the evidence presented in the manufacturer's submission and identified areas requiring clarification, for which the manufacturer provided additional evidence. Two phase III randomised controlled trials for a second-line population involving vortioxetine were identified-REVIVE and TAK318. These two trials represent only 972 of over 7000 patients included in trials of vortioxetine. In REVIVE, there was a statistically significant difference in depression scores favouring vortioxetine compared with agomelatine [mean Montgomery-Å sberg Depression Rating Scale (MADRS) score difference of 2.16 points; 95 % confidence interval 0.81-3.51]. The ERG concluded that, based on all the evidence, rather than the substantially restricted subset of evidence originally considered by the manufacturer, vortioxetine is likely to be similar in efficacy to other analysed antidepressants [citalopram, sertraline, escitalopram and venlafaxine extended release (XR)], and may be more efficacious than agomelatine and inferior to duloxetine. The ERG concluded that vortioxetine may be more tolerable than other analysed antidepressants (sertraline, venlafaxine XR and bupropion), although the limited data prevent firm conclusions. The base-case incremental cost-effectiveness ratio (ICER) of vortioxetine reported by the manufacturer was £378 per quality-adjusted life-year (QALY) compared with venlafaxine. Given considerable concerns about the indirect treatment comparison undertaken by the manufacturer, the use of only a restrictive subset of the available evidence, and concerns regarding comparators and structural model assumptions, the ERG believes that this is not a valid estimate of the cost effectiveness of vortioxetine. Following corrections made to the model made by the ERG, the estimated cost effectiveness of vortioxetine was sensitive to the source of evidence used, in addition to whether certain comparators were excluded. The NICE thus asked the manufacturer to provide a revised economic model, which incorporated the broader evidence base and considered the cost effectiveness of vortioxetine as a third-line treatment. Assuming equal efficacy, vortioxetine was shown to be less costly and generate a higher QALY gain than relevant comparators at the third-line of treatment owing to its tolerability and adverse event profile. The NICE Appraisal Committee recommended vortioxetine as an option for treating MDEs in adults whose condition has responded inadequately to two antidepressants within the current episode.
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Key Points for Decision Makers
Only limited data were presented to support the efficacy of vortioxetine as a second-line treatment for major depressive disorder.
The Evidence Review Group (ERG) concluded that, based on broader evidence, vortioxetine is likely to be similar in efficacy to other analysed antidepressants (citalopram, sertraline, escitalopram and venlafaxine extended release [XR] ), but may be more efficacious than agomelatine and inferior to duloxetine, in the treatment of major depression. The ERG concluded that vortioxetine may be more tolerable than other analysed antidepressants (sertraline, venlafaxine XR and bupropion), although the limited data prevent firm conclusions.
There was considerable uncertainty surrounding the manufacturer's cost-effectiveness estimates due to limitations in the evidence and the manufacturers' model.
Following the Appraisal Consultation Document (ACD), the manufacturer provided a revised economic model considering the cost effectiveness of vortioxetine as a third-line treatment. In this context, and assuming equal efficacy, vortioxetine was shown to be less costly and more effective, owing to its tolerability and adverse event profile, than the relevant comparators.
The National Institute for Health and Care Excellence Appraisal Committee recommended vortioxetine as an option for treating major depressive episodes in adults whose condition has responded inadequately to two antidepressants within the current episode.
Introduction
The National Institute for Health and Care Excellence (NICE) is an independent organisation responsible for providing national guidance to the National Health Service (NHS) in England and Wales on the use of selected new health technologies. Single technology appraisals (STAs) evaluate a single product, device or other technology that has a single indication, e.g. a new pharmaceutical product or licensed indication [1] . The manufacturer (or sponsor of the technology) submits the principal evidence supporting the clinical and cost effectiveness of the product, and an external independent academic organisation [the Evidence Review Group (ERG)] is commissioned to produce a review and critique of the evidence submitted [2] . Clinical specialists, NHS commissioning experts and patient experts also provide evidence for consideration by the NICE Appraisal Committee in formulating their guidance [1] . Once published, NICE technology guidance provides a legal obligation for NHS providers to reimburse technologies that have been approved [1] . This article presents a summary of the ERG report and subsequent development of NICE guidance for the use of vortioxetine for the treatment of a major depressive episode (MDE) with patients who have responded inadequately in terms of efficacy or tolerability to initial antidepressant treatment.
Full details of the relevant appraisal documents, including the appraisal scope, manufacturer submission, ERG report, Appraisal Consultation Document (ACD), Final Appraisal Determination (FAD) and responses to these documents, can be found on the NICE website [3] .
The Decision Problem
Vortioxetine (brand name Brintellix Ò ) is an antidepressant with a different mechanism of action to other antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), and has been claimed to act on a number of transmitter systems. The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) granted marketing authorisation on 18 December 2013 for the treatment of MDEs in people with major depressive disorder (MDD).
The final scope issued by the NICE identified a wide range of relevant comparators, including SSRIs, SNRIs, tricyclic antidepressants (TCAs), and other types of antidepressant and augmentation treatments. However, the manufacturer's submission considered a more restrictive decision problem, limiting attention to a 'switch' population, defined as patients who have responded inadequately in terms of efficacy or tolerability to initial antidepressant treatment, and who require and want to switch to an alternative antidepressant. The manufacturer justified this restriction by highlighting the potential unmet clinical and economic need for more effective and better-tolerated options for this group of patients. Accordingly, the manufacturer significantly restricted the number of eligible comparators to those that they considered represented alternatives in the proposed switch population. For moderate-to-severe MDEs, NICE Clinical Guideline 90 [4] recommends that when switching to another antidepressant, clinicians should consider switching initially to a different SSRI or a better-tolerated, newer-generation antidepressant, and subsequently to an antidepressant of a different pharmacological class that may be less well tolerated (e.g. venlafaxine), an older TCA (e.g. amitriptyline) or a monoamine oxidase inhibitor (MAOI; e.g. phenelzine). The manufacturer stated that the tolerability profile of vortioxetine, supported by the clinical efficacy data available within this population, was consistent with their proposed positioning of vortioxetine as an initial switch treatment within existing clinical pathways. The main comparators for vortioxetine as an initial switch therapy were considered by the manufacturer to be SSRIs and better tolerated, newer-generation antidepressants. The SNRIs (e.g. venlafaxine), TCAs and MAOIs were argued by the manufacturer to be reserved for subsequent switches due to tolerability issues.
Although the ERG acknowledged the justification provided by the manufacturer for restricting the patient population, this was also considered to represent an important limitation from both a clinical and cost-effectiveness perspective. The ERG considered that the appropriate population and potential position of vortioxetine should have been more formally demonstrated by the manufacturer, based on consideration of the full evidence base for vortioxetine and other comparators, rather than restricting the decision population and evidence base from the outset. Although vortioxetine has been studied in 24 completed trials (some of which were healthy volunteer trials) involving over 7000 patients, the manufacturer's submission focused largely on two studies considered relevant to the decision problem-REVIVE and TAK318.
The Independent Evidence Review Group (ERG) Review
The manufacturer provided a submission to the NICE on the use of vortioxetine for the treatment of an MDE with patients who have responded inadequately in terms of efficacy or tolerability to initial antidepressant treatment. The ERG critically reviewed the evidence presented in the manufacturer's submission by assessing (1) whether the submission conformed to NICE methodological guidelines; (2) whether the manufacturer's interpretation and analysis of the evidence were appropriate; and (3) the presence of other evidence or alternative interpretations of the evidence. In addition, the ERG identified areas requiring clarification, for which the manufacturer provided additional evidence [2] .
Clinical Evidence
The company conducted a systematic review of the literature to identify studies evaluating the clinical effectiveness and safety of vortioxetine for treating individuals with moderate-to-severe MDD who are experiencing an MDE and who have responded inadequately, in terms of efficacy or tolerability, to initial antidepressant treatment. Two phase III randomised controlled trials for a second-line population involving vortioxetine were identified-REVIVE and TAK318.
REVIVE was a 12-week, phase IIIb, non-inferiority RCT (n = 501) that assessed the efficacy and safety of vortioxetine versus agomelatine in adult patients with MDD who had not responded to initial antidepressant therapy. Patients were randomised to either the vortioxetine (10-20 mg daily; starting dose 10 mg daily), or agomelatine arm (25-50 mg daily; starting dose 25 mg daily). The primary outcome measure was change in Montgomery-Å sberg Depression Rating Scale (MADRS) score from baseline to week 8. 1 Secondary efficacy outcomes included response [defined as a C50 % decrease from baseline in MADRS total score or a Clinical Global Impression-Improvement scale (CGI-I) score B2], and remission [defined as a MADRS total score B10, or a CGISeverity scale (CGI-S) score B2].
There was a statistically significant difference in depression scores favouring vortioxetine compared with agomelatine [mean MADRS score difference of 2.16 points; 95 % confidence interval (CI) 0.81-3.51]. Vortioxetine was also superior to agomelatine in terms of response rate using MADRS at 8 weeks [odds ratio (OR) 1.81, 95 % CI 1.26-2.60] and remission rate (OR 1.72, 95 % CI 1.17-2.52). Vortioxetine and agomelatine had similar rates of treatment-emergent adverse events (approximately 54 %) and serious adverse events (approximately 1.5 %), but vortioxetine had lower rates of adverse events leading to withdrawal (5.9 vs. 9.5 %).
The TAK318 study was a multicentre, phase IIIb RCT (n = 447) that assessed the efficacy and safety of vortioxetine versus escitalopram in patients with well-treated MDD (CGI-S score B3) who were experiencing SSRIinduced sexual dysfunction. The population contained within TAK318 therefore represented a subset of the broader switch population where the reason for changing to a different antidepressant may be due to either tolerability issues (of which treatment-emergent sexual dysfunction is one possible example) or efficacy issues. As the primary outcome and population of this trial differed from those of the manufacturer's submission decision problem, this trial was not formally included in subsequent analyses.
The submission also included a systematic review of treatments other than vortioxetine in the switch population and an indirect treatment comparison with vortioxetine. Four trials were included in the indirect comparison and the outcomes assessed were remission rate and withdrawal rates due to adverse events.
The base-case indirect treatment comparison carried out by the company (see Fig. 1 ) was conducted in a frequentist framework using the Bucher et al. method [5] applied to risk differences, with results reported in Table 1 .
Vortioxetine had higher remission rates than all other treatments, but results were only statistically significant for agomelatine. The indirect treatment comparisons provided by the manufacturer and by Llorca et al. [9] both reported withdrawal due to adverse events, which can be considered a reasonable proxy for overall tolerability. Vortioxetine had lower rates of withdrawal due to adverse events than all other treatments, but results were only statistically significant for comparisons with sertraline, venlafaxine extended release (XR) and bupropion.
Critique of the Clinical Evidence
The ERG commented that REVIVE and TAK318 were appropriately conducted, but found that the two comparators considered in the trials were only of limited relevance to clinical practice in the UK (NICE has not issued any guidance for agomelatine-NICE, 2011 [6] ; and escitalopram is not commonly used). These two trials represent only 972 of over 7000 patients included in trials of vortioxetine. Only four trials were included in the primary indirect comparison of treatments. The ERG considers that the appropriate population and potential position of vortioxetine should have been based on a Fig. 1 Schematic of the company's indirect treatment comparison, adapted from the manufacturer's submission, available on the NICE website [3] . NICE National Institute for Health and Care Excellence, SSRI selective serotonin reuptake inhibitor, SNRI serotonin norepinephrine reuptake inhibitor, HDRS Hamilton Depression Rating Scale, MADRS Montgomery-Å sberg Depression Rating Scale broader consideration of the evidence for vortioxetine and other comparators. The ERG stated that the validity of the company's indirect treatment comparison was highly questionable given the differences in the baseline patient characteristics and severity of conditions of the populations across the four trials. For instance, in Kasper et al. [7] it was unclear whether the population consisted entirely of patients receiving second-line treatment. Across the four trials, there was considerable variation in the times of outcome assessment (varying from 6 to 14 weeks), which was considered likely to alter the results, assuming rates of remission and withdrawal are time-dependent. The ERG concluded that the heterogeneous nature of data included in the network meant that the results of any indirect treatment comparison may not be sufficiently reliable.
The manufacturer justified excluding trials of nonswitching populations by claiming that treatment efficacy in a switch population may be different from that in initial use. Given the limited nature of the data in the switch population, the ERG stated that data in non-switching and first-line populations should have been considered. The ERG noted that the company presented no evidence to suggest that the relative efficacy between non-SSRIs may vary between subsequent lines of treatment. The ERG stated that this restriction was inappropriate and evidence on non-switch populations was relevant when examining the efficacy and safety of vortioxetine. The ERG sought further evidence from the company on first-line population studies during the clarification stage.
The ERG identified two key meta-analyses: Pae et al. [8] and Llorca et al. [9] . Pae et al. [8] contains a meta-analysis of seven placebo-controlled trials with active reference treatment arms, whereas Llorca et al. [9] consists of an indirect treatment comparison that includes 57 placebocontrolled trials.
The data from Pae et al. [8] , comprising of comparisons of vortioxetine with agomelatine (one trial), duloxetine (five trials) and venlafaxine (one trial), were re-analysed by the ERG. The results for the remission outcome are shown in Table 2 .
Active reference arms are included in trials of antidepressants to assess whether patients are responding to therapy. An active reference should be a drug of proven superiority over placebo, to check whether the trial has successfully treated patients by confirming a difference between the active reference and placebo. In active reference arms, patients known to be non-responsive to the reference were excluded, possibly biasing results in favour of the active reference. While the ERG acknowledged this, it did not consider this potential bias to be substantial enough to exclude these trials. Pae et al. [8] found no evidence of any difference in efficacy between vortioxetine and venlafaxine, while vortioxetine was less effective than duloxetine in reducing depression scores or achieving response and remission. 2 The Llorca et al. [9] indirect treatment comparison includes 57 placebo-controlled trials of the following drugs: vortioxetine, agomelatine, desvenlafaxine, duloxetine, escitalopram, sertraline, venlafaxine, and vilazodone. A summary of the remission results from this study for relevant comparators for vortioxetine in the switch population under consideration are provided in Table 3 .
Llorca et al. [9] found no evidence of any difference in efficacy between vortioxetine and its comparators. However, there was evidence to suggest fewer people stop vortioxetine due to adverse events compared with other treatments, including sertraline and venlafaxine. The ERG considered that Llorca et al. [9] may provide the most reliable evidence comparing vortioxetine with other treatments.
Consistent with the findings of the company's indirect treatment comparison, the ERG concluded that, based on all the evidence, rather than the substantially restricted subset of evidence originally considered by the manufacturer, vortioxetine is likely to be similar in efficacy to other analysed antidepressants, but may be more efficacious than agomelatine and inferior to duloxetine. The ERG concluded that vortioxetine may be more tolerable than other analysed antidepressants, although the limited data prevent firm conclusions.
Cost-Effectiveness Evidence
The company did not identify any published studies of the cost effectiveness of vortioxetine in a second-line population. To evaluate cost effectiveness, the manufacturer's submission presented a decision model that evaluated the progression of a single MDE. The model was based on treatment success defined in terms of remission at 8 weeks. It followed-up patients for 12 months and considered three stages of disease progression: the acute phase (2 months' duration), a maintenance phase (6 months' duration), and a recovery phase (4 months' duration). The model used a decision tree to evaluate progression within the second-line of treatment, and a separate Markov process to describe further lines of therapy that may subsequently be used. The model schematic is reported in Fig. 2 .
The company conducted the economic analysis from an NHS and personal social services perspective, and chose a time horizon of 12 months, negating the need to discount costs and health effects. A half-cycle correction was applied to the health effects but not the costs in the Markov part of the model (cycle length 2 months).
The model was populated using various types of studies to inform the parameters. The probability of remission was taken from the indirect comparison conducted by the company, the results of which are reported in Table 1 . The probability of relapse for the maintenance phase was assumed to be the same for all treatments and was sourced from the study by Limosin et al. [10] . The probability of remission and relapse from subsequent lines of treatment were taken from the data obtained for a blend of treatments in the STAR*D study [11] . At all lines of treatment, the company considered that patients who had successfully followed 6 months of maintenance treatment without relapse had recovered. These patients stopped treatment and the company assumed that they could not experience recurrent depression.
Information on costs and health-related quality of life (HRQoL) was obtained from a variety of sources, depending on the phase in the model under consideration. Drug costs were calculated using a combination of trial data and the WHO Defined Daily Dose, and list prices from the Monthly Index of Medical Specialities. Resource use was taken from the PERFORM study for the acute phase, and from the study by Byford et al. [12] for longer-term outcomes, applying unit costs from Curtis [13] and NHS reference costs. HRQoL data for health states (e.g. baseline, remission, relapse) were obtained from the REVIVE trial for the acute phase, and from the study by Sapin et al. [14] for the maintenance phase, while disutilities for adverse events were taken from the study by Sullivan et al. [15] .
The base-case results presented by the company showed vortioxetine to have an incremental cost-effectiveness ratio (ICER) of £378 per quality-adjusted life-year (QALY) compared with venlafaxine (see Table 4 ). 
Critique of the Cost-Effectiveness Evidence
The ERG had a number of significant concerns regarding the model structure employed by the manufacturer. First, the ERG considered the model structure to be unnecessarily complicated and necessitated including additional crude assumptions regarding the timing of particular events. Second, the decision to base treatment success and decisions to switch therapy only on remission data reported at 8 weeks was considered an important limitation by the ERG. The third main structural concern identified by the ERG was the assumption that patients do not face a risk of subsequent relapse (or recurrence) in the recovery period. A final major structural limitation of the approach adopted by the manufacturer was the approach to modelling additional lines of treatment and the position of vortioxetine assumed within current sequential treatment. Although the manufacturer incorporated additional lines of therapy (e.g. third to fifth lines), the approaches to modelling these additional lines was relatively crude, such that rather than each line representing potentially distinct treatment options, subsequent therapies were assumed to reflect the costs and effects of a combination of different treatment options. While the ERG acknowledged that a full sequential analysis might be considered to be beyond the remit of an STA, the decision to only evaluate the cost effectiveness of vortioxetine at a single point in the pathway precluded a more appropriate demonstration that this was also the most efficient position. Consequently, this limited the conclusions that could be drawn from the associated results. Without such a consideration it was impossible to establish whether vortioxetine was more or less efficiently positioned as a first-line treatment or as a third, fourth or fifth line of treatment. The ERG commented that basing the decision model around remission data at 8 weeks was both unreflective of clinical practice and likely to introduce bias in the resulting estimates of cost effectiveness. Those patients whose condition partially responded to treatment, but who had not remitted, were treated in the same way in the model as those who had not responded, i.e. were assumed to switch onto third-line treatment at 4 weeks. The ERG explained that this ignored the costs of additional treatment for people whose disease responded but who did not go into remission. The ERG commented that the company also used the 8-week remission data in its original economic model to inform changes in treatment and utility at 4 weeks in the model. As a result, the health benefits of patients who went into remission may have been overestimated because the company's model assigned a utility value based on improved health improvements observed at 8 weeks rather than 4 weeks.
At the clarification stage, the company was asked to provide exploratory scenarios investigating the impact of an extended time horizon, given that the NICE recommends 2 years of continued treatment in people considered to be at high risk of relapse, and a relaxation of the assumption that patients in recovery receive no treatment or monitoring, while also having no probability of relapse. The company responded by providing two analyses-one in which a 2-year time horizon was assumed and another where treatment and monitoring costs were continued in a patient's recovery phase. The company's response showed that the results of their model were robust to these scenarios, but that each increased the ICER associated with vortioxetine.
The ERG highlighted that there was uncertainty around whether STAR*D was an appropriate study to inform the absolute probabilities regarding the prognosis of people with depression whose condition had not remitted after second-line treatment. This was for two reasons: STAR*D included treatments that did not reflect the comparators in the model, and the population of STAR*D was different from the population of REVIVE. Given the absence of other high-quality data to inform parameters at successive lines of treatment, the ERG considered that it would be preferable if STAR*D was used to inform relative differences between lines of treatment rather than absolute values.
The ERG presented deterministic ICERs for four exploratory analyses for second-line treatment using the company's original economic model, with minor Table 5 provides the results for these three effectiveness scenarios for the fourth exploratory analysis undertaken, where the rate of relapse was assumed to not vary by line of treatment, and where STAR*D was used to inform a proportionate reduction in effectiveness at each subsequent switch compared with the average of the remission rates for the comparators at the initial switch.
It is evident that the results were highly sensitive to the assumptions made regarding the relative effectiveness of the alternative treatments in achieving remission; however, the magnitude of the differences in costs and QALYs between these treatments appeared small across all scenarios. In particular, vortioxetine looks cost effective when equal effectiveness is assumed and SSRI comparators are excluded, which results from its better tolerability and less severe adverse event profile. One potential justification for excluding SSRI comparators would be if they have already been found to have inadequate response in the patient. This is more likely to be the case in the third, rather than second, line of treatment.
Conclusions of the ERG Review
The manufacturer's restriction to trials in a 'switch' population meant that very limited evidence was presented in the submission and the ERG considers the indirect treatment comparison, in particular, to be unreliable. Trials in the more general, non-switching population provide more data but with the possibility that treatment effects may differ from those patients switching treatments, particularly when comparing vortioxetine with SSRIs. Direct comparisons of vortioxetine to other treatments are limited because they are placebo-controlled trials with active reference arms, and therefore there is potential for bias due to them not being truly randomised. However, these trials suggested that vortioxetine may be inferior to duloxetine, and this possibility cannot be dismissed entirely, even with the potential for bias. Indirect comparisons of treatments suggested that vortioxetine had similar efficacy to other drugs but with the possibility of having a lower withdrawal rate due to adverse events. The ERG concludes, based on the totality of the evidence, that vortioxetine is likely to be of similar efficacy to other antidepressants but may be superior to agomelatine and inferior to duloxetine. Vortioxetine appears to have a lower withdrawal rate due to adverse events than most other treatments, and therefore may have a better overall tolerability profile; however, data on adverse events with vortioxetine are too limited to draw any firm conclusions on its safety. There are key structural issues that contribute to the uncertainty surrounding the bias of the estimated ICER in the manufacturer's base case, i.e. £378 for vortioxetine relative to venlafaxine. In particular, exclusion of first-line antidepressant therapy evidence means that the base-case model cannot be reliably used for this comparison and should only inform the estimation of cost effectiveness of vortioxetine against agomelatine. Having corrected utilities used in the model and employing an alternative set of assumptions regarding efficacy for lines of treatment beyond second-line treatments, the ERG found that vortioxetine was dominated by venlafaxine when the evidence from Llorca et al. [9] was used. When the evidence from Pae et al. [8] was used, vortioxetine had an ICER of £13,068 per QALY relative to venlafaxine (with the ICER of duloxetine relative to vortioxetine being £14,583 per QALY) and, with assumption of equal effectiveness across treatments, vortioxetine had an ICER of £28,270 per QALY relative to escitalopram (SSRI) and an ICER of £7992 per QALY relative to venlafaxine (SNRI). The ERG considered that this model was preferable to the company's original base case, but that there was still considerable uncertainty owing to restrictive assumptions around the positioning of vortioxetine in the treatment pathway and the exclusion of response from the decision model.
The National Institute for Health and Care
Excellence (NICE) Appraisal Committee:
Consideration of All Available Evidence
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of vortioxetine, having considered evidence on the nature of MDD and the value placed on the benefits of vortioxetine by people with this condition, those who represent them, and clinical experts. It also took into account the effective use of NHS resources.
Preliminary Guidance
Following the first Appraisal Committee meeting, and recorded in the ACD, the Committee stated that it was minded not to recommend vortioxetine within its marketing authorisation, i.e. for treating MDEs in adults. The Committee recommended that the NICE requested further clarification and analyses from the company for consideration at a second Appraisal Committee meeting. There was considerable uncertainty regarding whether or not approving vortioxetine would be cost effective. In particular, assuming equal effectiveness, the ERG had shown that vortioxetine was likely to be cost effective if SSRIs were excluded as comparators. This would be more appropriate in a third-line setting after SSRIs had failed in first-and second-line settings. The Committee therefore requested further analysis in order to clarify this issue and other model structure and parameterisation issues. Specifically, the Committee requested new analyses with a revised model structure, use of clinical data pertaining to the broader patient population, and consideration of the cost effectiveness of vortioxetine as a third-line treatment.
Manufacturer's Response to the Appraisal Consultation Document (ACD) Consultation
The company provided additional evidence in its response to the ACD. This additional evidence considered treatment of the third-line population and drew on evidence from a broader base than the restriction to switch population studies, as had been the case in the original submission. The manufacturer also further revised the model to address specific issues raised, including defining treatment success, and decisions to switch treatment, by both remission and response (rather than remission alone); adjusting the timing in the model regarding switching of treatment to that in the trials; a risk of relapse or recurrence at all stages of depression; using the ERG's suggested corrected utility values from REVIVE; and a 24-month time horizon (with discounting of costs and health effects after 12 months). Finally, since SSRIs are not used in the UK for a third-line population, they were not included as relevant comparators. The company stated that no evidence was available for the clinical effectiveness of vortioxetine in people having third-line treatment. In addition to evidence sources and assumptions considered previously, i.e. the original indirect treatment comparison, Pae et al. [8] , Llorca et al. [9] and equal efficacy, the company also included an additional trial-SOLUTION.
SOLUTION was an international, double-blind, randomised, active-control trial containing 410 East Asian adults assigned to either vortioxetine (10 mg daily) or venlafaxine (150 mg daily). Patients were recruited with recurrent moderate-to-severe MDD and no exclusions were based on the line of treatment used for their current MDE. They were assessed weekly during the first 2 weeks of treatment and then every 2 weeks until the end of the 8-week treatment period. The primary outcome measure in SOLUTION was the change from baseline in MADRS score at week 8. The mean change from baseline in MADRS total scores at week 8 was -19.4 points in the vortioxetine group and -18.2 points in the venlafaxine group, which resulted in a non-statistically significant mean difference of -1.2 points in favour of vortioxetine (95 % CI -3.0 to 0.6). At week 8, 43.1 % of the patient's MDEs had remitted in the vortioxetine group and 41.4 % in the venlafaxine group. The company considered that the SOLUTION trial was relevant to the decision problem because it directly compared vortioxetine with venlafaxine.
The company presented probabilistic pairwise ICERs, as well as a fully incremental analysis, for several scenarios using its revised economic model. The base-case results presented in Table 6 represent a model set in primary care, with a 6-month duration of maintenance therapy following treatment success.
Alternative scenarios considered the effects of the following on cost effectiveness: secondary care setting, implemented by applying different unit costs to resource use; a longer maintenance period of 22 months; and 30 % higher resource use of responders compared with remitters. As before, the most stark differences occur when comparing results between different assumptions about the appropriate source of evidence rather than through changes in the model's structural assumptions. The importance of the choice of the source of evidence can be seen in Table 6 , where vortioxetine is cost effective (dominant) at third-line treatment when equal efficacy is assumed, owing to its tolerability and adverse event profile, but is dominated by venlafaxine when effectiveness estimates are taken from Llorca et al. [9] .
ERG Critique of the Manufacturer's Response to the ACD Consultation
The company argued that there may be bias arising from the remission and response rates presented by Llorca et al. [9] since, for these outcomes, the results of several trials were missing. The ERG considered that this did not indicate a potential for bias and that the results for the mean change in MADRS score from Llorca et al., comprised of analysis of all included trials, were consistent with the results for the rates of response and remission. The ERG stated that SOLUTION was a well-conducted, randomised controlled trial. Although it did not reflect the population in England, the ERG considered that there was no reason to suspect that the relative effectiveness between vortioxetine and venlafaxine would differ substantially between patients in East Asia and England. The results from SOLUTION are seen as supporting previously presented evidence that vortioxetine is similarly effective to other non-SSRIs, but may be better tolerated.
The ERG considered that the company's revised economic model had used the most appropriate available data, and that the revised model structure, featuring both response and remission, more accurately reflected whether, in clinical practice in England, a person should continue or change treatment for their MDD.
The Appraisal Committee's Final Guidance
The responses to the preliminary guidance summarised in the ACD [3] , and the response submitted by the manufacturer, as well as the ERG's critique of this, were considered during a second meeting at which the Committee produced an FAD. Having reviewed the available data on the clinical and cost effectiveness of vortioxetine, having considered evidence on the nature of MDD and the value placed on the benefits of vortioxetine by people with the condition, those who represent them, and clinical experts, and taking into account the effective use of NHS resources, the Committee considered that vortioxetine should be recommended as an option for treating MDEs in adults whose condition has responded inadequately to two antidepressants within the current episode.
The Committee emphasised that there was no convincing clinical effectiveness evidence to show that vortioxetine was any more or less effective than other antidepressants. However, the Committee highlighted that, across all of the company's scenarios using its revised economic model, and when assuming equal efficacy between treatments, vortioxetine appeared to be a costeffective use of NHS resources compared with all other antidepressants.
The FAD forms the basis of the NICE guidance for the use of vortioxetine in the NHS in England and Wales [3] .
Key Methodological Issues

Clinical Effectiveness
The key methodological issues with respect to clinical efficacy were (1) the exclusion of broader evidence to inform evidence for second-line treatment for MDD; and (2) limitations of the indirect treatment comparison. The company failed to provide evidence that the relative efficacy of drugs was different between different lines of treatment, particularly between non-SSRI therapies. The ERG considered that this implied the need to use data from the broader evidence set to estimate relative efficacy for the second-line population, and not restrict evidence to that specifically collected on the second-line population. The company's indirect treatment comparison was highly limited because it was sparsely populated, and included heterogeneous populations and follow-up durations.
Cost Effectiveness
From the perspective of cost effectiveness, the restrictive consideration of vortioxetine at a specific line of treatment within a potential sequence of therapies was also the main issue. Not only does the line of treatment affect the relevance of different sources of evidence, as discussed above, but it also has implications for the care setting and the relevant comparators relative to which the incremental costs and health benefits of vortioxetine can be calculated.
The main areas of uncertainty in the cost-effectiveness evidence were (1) the insufficiency of using remission data at 8 weeks to solely inform efficacy where response is also clinically relevant and has implications for estimates of cost effectiveness; (2) the use of different sources for utilities that belong to different phases of the decision model; (3) the use of STAR*D to inform absolute remission and relapse probabilities for successive lines of treatment after second-line treatment; (4) employing a time horizon of 12 months when the NICE recommends continued treatment for at least 2 years for patients judged to be at high risk of relapse; and (5) the assumption of zero probability of relapse following 6 months of successful maintenance treatment.
NICE Guidance
Following the consultation on preliminary guidance, the NICE Appraisal Committee released the following final guidance to the NHS (ID583) [3] :
''Vortioxetine is recommended as an option for treating major depressive episodes in adults whose condition has responded inadequately to two antidepressants within the current episode.''
Interpretation of the Guidance
The ERG found that there was no convincing clinical effectiveness evidence to show that vortioxetine was any more or less effective than other antidepressants, but that it may be more tolerable. Estimates of the cost effectiveness of vortioxetine, when assuming equal efficacy between treatments, suggested it is an effective use of NHS resources as a third-line treatment compared with all other antidepressants. However, there is a considerable amount of uncertainty, owing to a number of assumptions that were made in order to generate the estimates of incremental costs and QALYs, including assumptions around the effectiveness of antidepressants (including vortioxetine) among the third-line population, given the lack of available evidence.
guidance not covered by the HTA report. This summary has not been externally peer reviewed by PharmacoEconomics.
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